Why I’d dump Neil Woodford’s Patient Capital to buy this millionaire-maker investment trust

Woodford Patient Capital Trust plc (LON: WPCT) is struggling to keep up with the market. Here’s one investment trust that could be a better buy.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Since its launch in 2015, the £653.3m shares in the Woodford Patient Capital Trust (LSE: WPCT) have lost 21%. 

For some comparison, over the same period the average fund in the IT UK All Companies sector has added 34%. That’s a performance gap of 55%!

Today, I’m going to look at the firm’s performance over the past three years and explain why the shares have lagged peers. I’ll also be looking at a trust that I believe could be a better buy. 

Long term investing 

When Neil Woodford launched Patient Capital, he did so as a protest against the rest of the investment industry, which he believes is too short-termist. Patient Capital was founded to invest with a long term outlook and not be constrained by the City’s performance obsession. 

Three years on from launch, Neil Woodford believes it’s still too early to judge the trust’s performance record. In a recent meeting with City analysts, he declared: “I could not be more confident that we will deliver on what we said three years ago when we launched Patient Capital. There has been quite a lot of commentary and the focus of that has been misjudged. We said we would deliver over a three to five-year period and we have only just got to the three-year point.

The problem is, Patient Capital’s short life has been dominated by high profile failures. Its most significant holding, shares in American biotech firm Prothena (at one point Woodford owned a third of the company), slumped 70% in April after it decided to discontinue the development of its lead drug. Shares in Allied Minds have also fallen following the writedown and disposal of its subsidiaries. These failures have eclipsed the smaller successes the trust has been able to achieve. 

As Patient Capital’s record shows, investing in early-stage companies is a tricky business. It’s virtually impossible to tell which businesses will succeed and which will fail.

This is why I’d avoid Woodford’s offering. Even though the star fund manager is confident in his stock picking abilities, I’d rather own an investment trust that holds already established businesses. EP Global Opportunities (LSE: EPG) is the perfect example. 

Global value 

The investment team at EP is on the lookout for undervalued investment opportunities around the world. The trust’s investment universe isn’t restricted. It can, and does, invest across the globe, giving investors exposure to economies they wouldn’t usually consider. 

Today, around 18% of net assets are invested in Japanese equities and 14% in the United States. Pharmaceutical giant Roche is the largest holding and healthcare is the most substantial sector exposure (18%). 

EP is globally diversified but what about its performance record? Well, since its inception (15 December 2003) EP’s net asset value per share has jumped 330% — including reinvestment of dividends. This performance track record, coupled with EP’s global equity exposure and exposure to the pharmaceutical sector, is enough to convince me that it’s a better buy than Patient Capital trust. 

My view is that, over the long term, EP will provide better, more consistent returns for investors without the additional risk of investing in start-up businesses.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Rupert Hargreaves owns no share mentioned. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

£10k in savings? These 2 gems could make £832 in passive income

Jon Smith outlines a couple of dividend shares with an average yield above 8% that could enhance a passive income…

Read more »

Growth Shares

This major UK bank just updated the forecast for the Rolls-Royce share price

Jon Smith talks through an analyst forecast for the Rolls-Royce share price and explains why he thinks further gains could…

Read more »

Middle-aged white male courier delivering boxes to young black lady
Investing Articles

This FTSE 100 share looks like a Black Friday bargain for me!

Our writer explains why he recently took the opportunity to buy this ultra-cheap FTSE 100 share after its 39% year-to-date…

Read more »

Investing Articles

What will happen to the stock market in 2025? Here’s what the experts say

The UK stock market did well at the start of this year but has faltered towards the end. Our writer…

Read more »

Investing Articles

After plunging nearly 40%, I’m considering buying this bargain FTSE 100 stock

Paul Summers has been running the rule over one of the year's biggest FTSE 100 losers. Is a screamingly cheap…

Read more »

Ice cube tray filled with ice cubes and three loose ice cubes against dark wood.
Investing Articles

Just released: this month’s lower-risk, higher-yield Share Advisor recommendation [PREMIUM PICKS]

Ice ideas will usually offer a steadier flow of income and is likely to be a slower-moving but more stable…

Read more »

Investing Articles

Should I buy growth or value in my Stocks and Shares ISA?

Here’s why Stephen Wright's looking past the difference between growth stocks and value shares when finding investments for his ISA.

Read more »

Young mixed-race woman jumping for joy in a park with confetti falling around her
Investing Articles

If I’d invested £5,000 in a Nasdaq index fund 5 years ago, here’s how much I’d have now

The Nasdaq index keeps hitting new all-time records in 2024, as US tech stocks fly. How much could I have…

Read more »